Nevertheless, the presence of lymphatics and HEV in TLO, even at advanced stages of prostate cancer, is indicating that dendritic cell or CD8 T cell-based therapies could be attractive adjuvant therapies, which can exploit the navigation systems of residual TLO to stimulate prostate cancer regression. This evidence concerns the gene CD8A and prostate cancer.